A Phase 2, Open-Label, Randomized Controlled Trial Evaluating Safety and Efficacy of Dose-Intensified Versus Standard Dosing Regimens of [177Lu]Lu-PSMA-597 in mCRPC (OPTIMAL-PSMA).
Researchers tested optimized dosing schedules for a targeted radiation therapy in advanced prostate cancer, informing safer treatment protocols.
OPTIMAL-PSMA Phase 2 RCT evaluated dose-intensified vs standard [177Lu]Lu-PSMA-597 dosing regimens in mCRPC, providing safety and efficacy data to optimize radioligand therapy dosing in the PSMA-targeted radionuclide therapy field. This record was retained from the prior triage attempt for PubMed pipeline handoff.
What the study was
- Study design
- Phase 2 open-label randomized controlled trial (OPTIMAL-PSMA)
- Category
- sentinel
- Maturity
- Potentially Practice-Changing
- Journal
- J Nucl Med
Why it surfaced
PSMA radioligand therapy is one of the most active areas in prostate cancer treatment. A Phase 2 RCT in J Nucl Med addressing dose optimization for Lu-PSMA-597 is directly relevant to treatment planning and future regulatory submissions in this rapidly evolving space.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.